Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal booster strategy for SARS-CoV-2 vaccination in kidney transplant patients
NL-OMON50602Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elasomeran and Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University Medical Center Groningen. Primary endpoint: Primary responder rate at day 28. Started Nov 2021; status: active, not recruiting.
02
Drugs
elasomeranAd26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50602.